◆ mixed
Impact
PhaseApproved
Time to marketAlready approved and commercially available in the US since January 2026. European approval is not expected after the CHMP's final negative opinion in October 2026.
YARTEMLEA narsoplimab Updated Oct 31
What to watch
Watch the Q3 2026 earnings report on November 11, 2026 for YARTEMLEA's sales trajectory. The key question is whether the 190% sequential growth rate from Q1 to Q2 can be sustained or if the launch is plateauing. Separately, the zaltenibart (OMS906) Phase 3 PNH data readout expected in Q4 2026 is a major pipeline catalyst for the stock, though it is a different drug.
Bull case
- First and only approved therapy for TA-TMA, a life-threatening condition with no prior approved treatments, giving YARTEMLEA a market monopoly in the US
- Commercial sales are ramping rapidly: gross revenue grew 190% sequentially from $11.1M in Q1 to $32.2M in Q2 2026, and the company reached GAAP net income of $13.2M in Q2
- Analyst consensus is strongly bullish: 8 Buy/Strong Buy ratings vs 2 Hold, with a mean price target of $27.50 (45% upside from the recent $18.95 close)
Bear case
- The EMA's CHMP issued a final negative opinion on narsoplimab for TA-TMA in October 2026 after re-examination, blocking access to the European market
- The FDA approval was based on a single-arm, open-label study of only 28 patients, a relatively thin evidence base that the EMA found insufficient
- Multiple insiders (VP of Finance, General Counsel, Chief Accounting Officer) sold shares in August-September 2026, with some sales not under 10b5-1 plans